they only had a 5% screening yield in Everest, procedure takes ~4 hours and has a 30% cross over to surgical repair. Surgical leaflet plication as a stand alone procedure does not work and is routinely coupled with annuloplasty. Even this has a low long-term success rate.
The data were presented today by Saibal Kar, M.D., director of interventional cardiac research at Cedars-Sinai Medical Center and the lead enrolling investigator of the EVEREST trials.
"The High Risk Registry data support our belief that the MitraClip therapy is a safe and clinically beneficial treatment alternative for select patients suffering from significant functional or degenerative MR," said Dr. Kar. "Patients otherwise unable to withstand more invasive treatments can benefit from the MitraClip therapy while avoiding the risk of increased morbidity and mortality often associated with surgical treatment."